Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HK1 | P19367 | 3/20 | 0.39 |
| ▸ | HK2 | P52789 | 3/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038560 | 1.00 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL8038552 | 1.00 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL25723433 | 0.86 | ALDH1A1 (0.42) | MAPK1ALDH1A1THRBLMNACYP2C19 | |
| SCHEMBL25722481 | 0.86 | ALDH1A1 (0.42) | MAPK1ALDH1A1THRBLMNACYP2C19 | |
| SCHEMBL18391246 | 0.86 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL4314010 | 0.86 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL26229737 | 0.86 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL13240509 | 0.86 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL25499747 | 0.86 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL24133149 | 0.85 | LMNA (0.50) | MAPK1ALDH1A1THRBLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| EP-3134093-B1 | ANALOGS OF N-ACETYLGLUCOSAMINE AND USES THEREOF | UNIV CALIFORNIA (US) | 2020-09-09 | — | — | EP | claimed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | MAPK1 2264/4885AMDHD2 715/4885ALDH1A1 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.